# An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

> **NCT05809531** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- C3G
- IC-MPGN
- C3 Glomerulopathy
- C3 Glomerulonephritis
- Complement 3 Glomerulopathy
- Complement 3 Glomerulopathy (C3G)
- Complement 3 Glomerulonephritis
- Dense Deposit Disease
- DDD
- Membranoproliferative Glomerulonephritis
- Membranoproliferative Glomerulonephritis (MPGN)
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

## Interventions

- **DRUG:** Pegcetacoplan

## Key facts

- **NCT ID:** NCT05809531
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-29
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05809531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05809531, "An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05809531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*